Multicentre Comparison of a Diagnostic Assay: Aquaporin-4 Antibodies in Neuromyelitis Optica

Objective: Antibodies to cell surface central nervous system proteins help to diagnose conditions which often respond to immunotherapies. The assessment of antibody assays needs to reflect their clinical utility. We report the results of a multicentre study of aquaporin (AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis optica spectrum disorders (NMOSD).

Methods: Coded samples from patients with neuromyelitis optica (NMO) or NMOSD (101) and controls (92) were tested at 15 European diagnostic centres using 21 assays including live (n=3) or fixed cell-based assays (n=10), flow cytometry (n=4), immunohistochemistry (n=3) and ELISA (n=1).

Results: Results of tests on 92 controls identified 12assays as highly specific (0-1 false-positive results). 32 samples from 50 (64%) NMO sera and 34 from 51 (67%) NMOSD sera were positive on at least two of the 12 highly specific assays, leaving 35 patients with seronegative NMO/spectrum disorder (SD). On the basis of a combination of clinical phenotype and the highly specific assays, 66 AQP4-Ab seropositive samples were used to establish the sensitivities (51.5-100%) of all 21 assays. The specificities (85.8-100%) were based on 92 control samples and 35 seronegative NMO/SD patient samples.

Conclusions: The cell-based assays were most sensitive and specific overall, but immunohistochemistry or flow cytometry could be equally accurate in specialist centres. Since patients with AQP4-Ab negative NMO/SD require different management, the use of both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate these assays in a clinically meaningful way. The process described here can be applied to the evaluation of other antibody assays in the newly evolving field of autoimmune neurology.

Citing Articles

Novel Automated Chemiluminescent Immunoassay for the Detection of Autoantibodies Against Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders.

Yamazaki N, Takahashi T, Misu T, Nishikawa Y Diagnostics (Basel). 2025; 15(3).

PMID: 39941228 PMC: 11816824. DOI: 10.3390/diagnostics15030298.

Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing.

Lleixa C, Titulaer M, Rohrbacher S, Mgbachi V, Halstead S, Fehmi J J Peripher Nerv Syst. 2025; 30(1):e70000.

PMID: 39887819 PMC: 11780190. DOI: 10.1111/jns.70000.

Thalamic volume differentiates multiple sclerosis from neuromyelitis optica spectrum disorder: MRI-based retrospective study.

Alosaimi M, Alkanhal H, Aldeligan S, Alkhawajah N, Albishi A, Hilabi B Front Neurol. 2025; 15():1491193.

PMID: 39830197 PMC: 11739352. DOI: 10.3389/fneur.2024.1491193.

Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.

Kim S, Gomes A, Schindler P, Hyun J, Kim K, Lee D JAMA Neurol. 2024; 82(2):168-175.

PMID: 39714824 PMC: 11811799. DOI: 10.1001/jamaneurol.2024.4400.

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.

Nicolescu M, Haussler V, Paul F, Oertel F, Schindler P, Strobl J J Neurol. 2024; 272(1):86.

PMID: 39708205 DOI: 10.1007/s00415-024-12803-5.

References

Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-12. DOI: 10.1016/S0140-6736(04)17551-X. View

Lennon V, Kryzer T, Pittock S, Verkman A, Hinson S . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473-7. PMC: 2212860. DOI: 10.1084/jem.20050304. View

Polman C, Reingold S, Edan G, Filippi M, Hartung H, Kappos L . Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. DOI: 10.1002/ana.20703. View

Weinshenker B, Wingerchuk D, Vukusic S, Linbo L, Pittock S, Lucchinetti C . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59(3):566-9. DOI: 10.1002/ana.20770. View

Wingerchuk D, Lennon V, Pittock S, Lucchinetti C, Weinshenker B . Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10):1485-9. DOI: 10.1212/01.wnl.0000216139.44259.74. View

Dalmau J, Tuzun E, Wu H, Masjuan J, Rossi J, Voloschin A . Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61(1):25-36. PMC: 2430743. DOI: 10.1002/ana.21050. View

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130(Pt 5):1235-43. DOI: 10.1093/brain/awm062. View

Matiello M, Lennon V, Jacob A, Pittock S, Lucchinetti C, Wingerchuk D . NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008; 70(23):2197-200. DOI: 10.1212/01.wnl.0000303817.82134.da. View

Hutchinson M, Waters P, McHugh J, Gorman G, ORiordan S, Connolly S . Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008; 71(16):1291-2. DOI: 10.1212/01.wnl.0000327606.50322.f0. View

10.

Lai M, Hughes E, Peng X, Zhou L, Gleichman A, Shu H . AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009; 65(4):424-34. PMC: 2677127. DOI: 10.1002/ana.21589. View

11.

Florance N, Davis R, Lam C, Szperka C, Zhou L, Ahmad S . Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009; 66(1):11-8. PMC: 2826225. DOI: 10.1002/ana.21756. View

12.

Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J . Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2009; 9(1):67-76. PMC: 2824142. DOI: 10.1016/S1474-4422(09)70324-2. View

13.

Graus F, Saiz A, Dalmau J . Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2009; 257(4):509-17. DOI: 10.1007/s00415-009-5431-9. View

14.

Lai M, Huijbers M, Lancaster E, Graus F, Bataller L, Balice-Gordon R . Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010; 9(8):776-85. PMC: 3086669. DOI: 10.1016/S1474-4422(10)70137-X. View

15.

Irani S, Alexander S, Waters P, Kleopa K, Pettingill P, Zuliani L . Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010; 133(9):2734-48. PMC: 2929337. DOI: 10.1093/brain/awq213. View

16.

Lancaster E, Huijbers M, Bar V, Boronat A, Wong A, Martinez-Hernandez E . Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011; 69(2):303-11. PMC: 3059252. DOI: 10.1002/ana.22297. View

17.

Vincent A, Bien C, Irani S, Waters P . Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011; 10(8):759-72. DOI: 10.1016/S1474-4422(11)70096-5. View

18.

Waters P, McKeon A, Leite M, Rajasekharan S, Lennon V, Villalobos A . Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78(9):665-71. PMC: 3286228. DOI: 10.1212/WNL.0b013e318248dec1. View

19.

Leite M, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D . Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012; 78(20):1601-7. PMC: 3348852. DOI: 10.1212/WNL.0b013e31825644ff. View

20.

Titulaer M, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T . Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2):157-65. PMC: 3563251. DOI: 10.1016/S1474-4422(12)70310-1. View